CRE RESPOND PhD student Getnet Mengistu Assefa has published new research in Critical Care that provides important insights into optimising antibiotic therapy for critically ill patients.
The study, Optimising tazobactam dosing in critically ill adult patients without renal replacement therapy: a population pharmacokinetic analysis of individual patient data pooled from multiple clinical studies, addresses a significant evidence gap in the dosing of β-lactam/β-lactamase inhibitor therapies commonly used to treat serious infections.
Conducted in collaboration with an international team of researchers, the study analysed individual patient data from nine clinical studies involving 421 critically ill patients. Using advanced population pharmacokinetic modelling, the researchers characterised how tazobactam is processed in the body and evaluated whether current dosing regimens achieve therapeutic targets.
The findings suggest that standard tazobactam dosing may not provide adequate drug exposure in critically ill patients with augmented renal clearance, a condition that can lead to faster drug elimination. The research highlights the need for dose optimisation strategies in selected patient populations to help ensure effective treatment outcomes.
As first author, Getnet led this work as part of his PhD research through CRE RESPOND and the University of Queensland's Frazer Institute.
"This study contributes to our understanding of how we can better individualise antibiotic therapy for critically ill patients," said Getnet. "By improving dosing strategies, we can help maximise treatment effectiveness and support better patient outcomes."
The publication represents an important contribution to the growing body of research focused on precision dosing and antimicrobial optimisation in critical care settings.
CRE RESPOND congratulates Getnet and his supervisors, Dr Fekade Sime and Professor Jason Roberts, together with their international collaborators, on this outstanding achievement.
